Literature DB >> 24108440

Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.

Nina V Kraguljac1, David M White, Meredith A Reid, Adrienne C Lahti.   

Abstract

IMPORTANCE: Alterations in glutamatergic neurotransmission have been postulated to be a key pathophysiologic mechanism in schizophrenia.
OBJECTIVE: To evaluate hippocampal volumetric measures and neurometabolites in unmedicated patients with schizophrenia and the correlations between these markers. Our a priori hypothesis was that glutamate levels would negatively correlate with hippocampal volume in schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Combined 3-T structural magnetic resonance imaging and single-voxel proton magnetic resonance spectroscopy study at the Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, of 27 unmedicated patients with schizophrenia and 27 healthy controls. MAIN OUTCOMES AND MEASURES: Hippocampal volumetric measures and neurometabolites, and the correlations between volumetric measurements and neurometabolites.
RESULTS: Hippocampal volumetric deficits, increased ratios of hippocampal glutamate and glutamine to creatine (Glx/Cr), and a loss of correlation between hippocampal N-acetylaspartate (NAA)/Cr and Glx/Cr in patients with schizophrenia were found. Significant correlations between hippocampal volumetric measures and Glx/Cr were also found in patients with schizophrenia but not healthy controls. CONCLUSIONS AND RELEVANCE: Our findings support the theory that alterations in hippocampal glutamate levels potentially account for structural deficits in the hippocampus observed in schizophrenia neuroimaging studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108440      PMCID: PMC7891898          DOI: 10.1001/jamapsychiatry.2013.2437

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  62 in total

1.  Hippocampal pathologic findings in schizophrenia. A morphometric study.

Authors:  D V Jeste; J B Lohr
Journal:  Arch Gen Psychiatry       Date:  1989-11

Review 2.  Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies.

Authors:  R Grant Steen; Courtney Mull; Robert McClure; Robert M Hamer; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2006-06       Impact factor: 9.319

3.  Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.

Authors:  Ludger Tebartz van Elst; Gabi Valerius; Martin Büchert; Thorsten Thiel; Nicholas Rüsch; Emanuel Bubl; Jürgen Hennig; Dieter Ebert; Hans M Olbrich
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

4.  Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions.

Authors:  S E Arnold; B R Franz; R C Gur; R E Gur; R M Shapiro; P J Moberg; J Q Trojanowski
Journal:  Am J Psychiatry       Date:  1995-05       Impact factor: 18.112

5.  Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia.

Authors:  R F Deicken; M Pegues; D Amend
Journal:  Schizophr Res       Date:  1999-06-22       Impact factor: 4.939

6.  Anterior cingulate and cerebellar GABA and Glu correlations measured by ¹H J-difference spectroscopy.

Authors:  Kevin W Waddell; Parham Zanjanipour; Subechhya Pradhan; Lei Xu; Edward B Welch; James M Joers; Peter R Martin; Malcolm J Avison; John C Gore
Journal:  Magn Reson Imaging       Date:  2010-09-29       Impact factor: 2.546

7.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging.

Authors:  A Bertolino; S Nawroz; V S Mattay; A S Barnett; J H Duyn; C T Moonen; J A Frank; G Tedeschi; D R Weinberger
Journal:  Am J Psychiatry       Date:  1996-12       Impact factor: 18.112

8.  Subanesthetic doses of ketamine stimulate psychosis in schizophrenia.

Authors:  A C Lahti; B Koffel; D LaPorte; C A Tamminga
Journal:  Neuropsychopharmacology       Date:  1995-08       Impact factor: 7.853

9.  Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.

Authors:  Scott A Schobel; Nicole M Lewandowski; Cheryl M Corcoran; Holly Moore; Truman Brown; Dolores Malaspina; Scott A Small
Journal:  Arch Gen Psychiatry       Date:  2009-09

10.  Hippocampal neuron number in schizophrenia. A stereological study.

Authors:  S Heckers; H Heinsen; B Geiger; H Beckmann
Journal:  Arch Gen Psychiatry       Date:  1991-11
View more
  91 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  Dysregulated Maturation of the Functional Connectome in Antipsychotic-Naïve, First-Episode Patients With Adolescent-Onset Schizophrenia.

Authors:  Meiling Li; Benjamin Becker; Junjie Zheng; Yan Zhang; Heng Chen; Wei Liao; Xujun Duan; Hesheng Liu; Jingping Zhao; Huafu Chen
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

5.  Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T.

Authors:  Petr Bednařík; Amir Moheet; Dinesh K Deelchand; Uzay E Emir; Lynn E Eberly; Martin Bareš; Elizabeth R Seaquist; Gülin Öz
Journal:  NMR Biomed       Date:  2015-04-22       Impact factor: 4.044

6.  Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.

Authors:  Eric Plitman; Raihaan Patel; Jun Ku Chung; Jon Pipitone; Sofia Chavez; Francisco Reyes-Madrigal; Gladys Gómez-Cruz; Pablo León-Ortiz; M Mallar Chakravarty; Camilo de la Fuente-Sandoval; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2016-06-08       Impact factor: 7.853

7.  Developmental timing and critical windows for the treatment of psychiatric disorders.

Authors:  Oscar Marín
Journal:  Nat Med       Date:  2016-10-26       Impact factor: 53.440

Review 8.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

9.  N-acetylaspartate normalization in bipolar depression after lamotrigine treatment.

Authors:  Paul E Croarkin; M Albert Thomas; John D Port; Joshua M Baruth; Doo-Sup Choi; Osama A Abulseoud; Mark A Frye
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

10.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.